==== Front Ann Gen Psychiatry Ann Gen Psychiatry Annals of General Psychiatry 1744-859X BioMed Central London 37381041 455 10.1186/s12991-023-00455-0 Research Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-naïve schizophrenia patients Zeng Kuan 12 Wang Shuo 12 Zhang Lin 12 Zhang Yanting 1210103465@qq.com 4 Ma Jun majun0313@msn.cn 123 1 grid.33199.31 0000 0004 0368 7223 Department of Psychiatry, Wuhan Mental Health Center, No. 89, Gongnongbing Road, Wuhan, Hubei China 2 Wuhan Hospital for Psychotherapy, Wuhan, China 3 grid.412632.0 0000 0004 1758 2270 Department of Psychiatry, Renmin Hospital, Wuhan University, Wuhan, China 4 grid.452825.c 0000 0004 1764 2974 Department of Psychiatry, Suzhou Guangji Hospital, No. 11, Guangqian Road, Suzhou, Jiangsu China 28 6 2023 28 6 2023 2023 22 255 4 2023 7 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Background Metabolic syndromes (MetS) are clinical syndromes involving multiple pathological states with distinct gender-specific clinical patterns. As a serious disorder associated with psychiatric conditions, the prevalence of MetS is significantly higher in the population with schizophrenia (Sch). The aim of this paper is to report gender differences in the prevalence, associated factors and severity-related factors of MetS in first-treatment and drug-naïve (FTDN) patients with Sch. Methods A total of 668 patients with FTDN Sch were included in this study. We collected socio-demographic and general clinical information on the target population, measured and evaluated common metabolic parameters and routine biochemical indicators, and assessed the severity of psychiatric symptoms using Positive and Negative Symptom Scale (PANSS). Results In the target group, the prevalence of MetS was significantly higher in women (13.44%, 57/424) than in men (6.56%, 16/244). In the males, waist circumference (WC), fasting blood glucose (FBG), diastolic blood pressure (DBP), and triglycerides (TG) were risk factors for MetS, while systolic blood pressure (SBP), TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and platelet (PLT) were risk factors for the females. More importantly, for the females, we found that age, LDL-C, PANSS scores and blood creatinine (CRE) were risk factors for higher MetS scores, while onset age and hemoglobin (HGB) were protective factors. Conclusion There are significant gender differences in the prevalence of MetS and its factors among patients with FTDN Sch. The prevalence of MetS is higher and the factors that influence MetS are more numerous and extensive in females. The mechanisms of this difference need further research and clinical intervention strategies should be formulated with gender differences. Keywords Gender differences Metabolic syndrome Schizophrenia First-treatment Drug-naïve issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023 ==== Body pmcIntroduction Metabolic syndrome (MetS) is defined as a pathological condition with multiple components including insulin resistance, atherosclerotic dyslipidemia, central obesity and hypertension, which is significantly associated with an increased risk of developing diabetes and cardiovascular disease (CVD) [1]. With the development of global health care, this disease has replaced infectious diseases as the main look hazard in the modern world [2]. According to statistics, MetS affects about a quarter of the world's population [3] and an epidemiological study show that its prevalence is increasing every year [4, 5]. According to national stream surveys in China, the prevalence of MetS has gradually increased from 13.7% in 2000–2001 [6] to 31.1% in 2015–2017 [7]. Another important characteristic of MetS is the significant gender difference, with women having a significantly higher risk of prevalence compared to men [6–9]. Therefore, we believe that appropriate health management measures for metabolic syndrome in men and women, equally and differently, are important medical topics, especially in patients with schizophrenia (Sch), a population with a high prevalence of MetS that seems to be more critical [10]. Sch is a serious and highly disabling psychiatric disorder [11] that affects approximately 1% of the world's population [12] and reduces life expectancy by 15–20 years [13], with comorbid MetS being a significant direct or indirect contributor to this reduction [14–17]. Atypical antipsychotics (APs) are the primary and most commonly used treatment for Sch, but unacceptably, these drugs have complex mechanisms of adverse effects leading to metabolic disorders [18, 19], and the incidence of MetS in patients taking them can be as high as 22.4–63%, three times that of the general population [20]. However, it does not seem reasonable to attribute the high prevalence of MetS in patients with Sch all to APs exposure, as there are indications that metabolic disturbances in schizophrenic patients predate being prescribed antipsychotics [21]. Numerous studies have shown that even in a drug-naïve state, patients with Sch also experience significantly higher levels of insulin resistance [22, 23], high body mass index and obesity rates [24], and higher rates of impaired glucose tolerance [25] than the healthy population. It seems that we can find that Sch itself is a risk factor for MetS, or that the disease has a predisposition to MetS. Therefore, it is crucial to conduct research on the MetS for the population diagnosed with Sch. The research on gender differences in Sch is equally compelling. Several studies have found negative symptoms more often in male patients [26], while affective symptoms are more prominent in female patients [27]. In terms of disease course, women appear to have higher remission rates, lower relapse rates [28] and a better prognosis [29] than men. Admittedly, gender differences in the metabolic disorders of Sch are of equal concern to psychiatrists. For example, male patients with a first-episode Sch are more likely than females to develop insulin resistance and abnormal lipid levels [30]. The prevalence of diabetes in patients with Sch on long-term antipsychotic medication is significantly higher in women (27%) than in men (17%) [31]. In addition, only body mass index in female patients is associated with brain-derived neurotrophic factor (BDNF) [32]. However, most of the currently known studies focus on selected indicators of MetS components and lack exploration of MetS as a whole [33, 34], or have small sample sizes [35–37], or do not explore in greater depth the factors associated with MetS severity [34, 36]. In our study, building on previous studies of gender differences in both Sch and MetS, we will report gender differences in the prevalence and influencing factors of MetS in a larger sample of patients with first-treatment and drug-naïve (FTDN) Sch and dig deeper into gender differences in factors associated with MetS severity, with a view to informing clinical interventions for MetS in this subgroup of the population across gender. Materials and methods Subjects From February 2017 to June 2022, a total of 668 patients with FTDN Sch were enrolled at the Wuhan Mental Health Center. The mean age of the patients was 29.58 ± 7.18 years, and 63.47% of the patients were female. Inclusion criteria: The patients included in our study met the 10th revision of the International Classification of Diseases (ICD-10) schizophrenia diagnostic criteria. They were aged between 18 and 49 years, with no gender specification. The Positive and Negative Symptom Scales (PANSS) score, used to assess the degree of psychopathology, was at least 60. Prior to this assessment, there were no records of antipsychotic exposure, and benzodiazepines were not prohibited for use. Additionally, our investigation did not exclude patients with comorbid, unmedicated metabolic system illnesses such as hypertension, hyperlipidemia, diabetes mellitus, and obesity. Exclusion criteria All patients under the age of 18 and patients with other mental illnesses, such as bipolar disorder, depression, intellectual developmental disorders, substance abuse or dependency, were not included. Also, we disqualified those with coexisting, severe somatic illnesses, autoimmune disorders, surgeries of any kind within the last 6 months. Any patient with a previously established metabolic disorder and on therapeutic medication (e.g., antihypertensives, hypoglycemic drugs, lipid-lowering drugs, etc.) will also be excluded. Withdrawal criteria Patients who cannot be definitively diagnosed within a short period of time will be followed up for a further 14 days. If the patient is still unable to be diagnosed, then they will be withdrawn from the study. The study was reviewed and approved by the Ethics Committee of Wuhan Mental Health Center, and all participants signed a written informed consent form. Research design This cross-sectional study intended to compare gender differences in MetS prevalence and to analyze the associated factors affecting MetS and its severity among patients with FTDN Sch. A self-made spreadsheet was used to collate the socio-demographic and general clinical information of the patients included. On the second day of the patient's admission, we extracted the patient's recurring blood, biochemical signs, thyroid function, and many others, from the digital medical file gadget. These included the patient's red blood cell (RBC), hemoglobin (HGB), white blood cell (WBC), platelet (PLT), fasting blood glucose (FBG), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN), blood creatinine (CRE), blood uric acid (UA), thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free tetraiodothyronine (FT4), systolic blood pressure (SBP), diastolic blood pressure (DBP). Diagnostic criteria of metabolic syndrome: the diagnostic criteria for metabolic syndrome in China require that at least three of the following five indicators be met [38]: 1. abdominal obesity: waist circumference (WC) ≥ 90 cm in men and ≥ 85 cm in women. 2. Hyperglycemia: FBG ≥ 6.1 mmol/L and/or those who have been diagnosed and treated for diabetes mellitus. 3. Hypertension: SBP ≥ 130/85 mmHg or DBP ≥ 85 mmHg or confirmed and treated hypertension. 4. TG ≥ 1.70 mmol/L. 5. HDL-C < 1.04 mmol/L. Assessment of psychopathology: four uniformly trained attending psychiatrists used the PANSS and Clinical Global Impression Scale—Severity of Illness (CGI-SI) to assess the severity of psychiatric symptoms on the day of patient admission. We also divided PANSS into five factors (including positive factor, negative factor, excitement factor, anxiety/depression factor, cognitive factor) for inclusion in the statistical analysis during the actual operation, as reported by Jong-Hoon Kim et al. [39]. Scoring rules for MetS: based on previous studies, we have scored the severity of the MetS in clinical subgroups of the MetS [40, 41]. According to the scoring rules, we first calculated the reciprocal of HDL-C and mean average pressure (MAP). MAP was calculated as MAP = 1/3×SBP+2/3×DBP. Then we normalized the new five parameters of the metabolic syndrome obtained (WC, TG, reciprocal of HDL-C, FBG and MAP, respectively). In the third step, the five normalized components were subjected to a principal component analysis with varimax rotation to drive PCs (eigenvalue 1.0) that accounted for a significant portion of the observed variation. In the present study, PC1 and PC2 explained 37.75% and 21.94% of the variance, respectively [loadings PC1 (PC2): WC 0.53 (-0.56), TG 0.66 (− 0.05), HDL 0.82 (0.14), MAP 0.30(0.87) and FBG − 0.64 (0.08)]. The weight of the PC score was determined by the relative weights of PC1 and PC2 in the explained variance. The individual weighted PC scores were then added up to create the MetS score. Data analysis The categorical variables are stated in terms of counts, while the data acquired for the normally distributed continuous measures are reported in terms of mean and standard deviation. T-tests on independent samples were employed to compare continuous variable from various groups. Chi-squared tests were used to compare rates. To compare gender differences in comorbid abnormal glucose metabolism and clinical parameters, we used 2 × 2 ANOVAs, taking into account gender (2 levels: male and female) and diagnosis (2 levels: with MetS and without MetS) and the main effects of gender and subclinical groups, as well as the interaction between gender × diagnosis groups, were tested. Further, separate ANOVAs were performed in the male and female groups to compare the differences in clinical parameters between the subclinical groups that did and did not have MetS. We also calculated Pearson correlation coefficients to assess the association between MetS and the other variables (exclusion of MetS components). And then, binary logistic regression analysis was used to explore the correlations of MetS in the included samples both the males and females. Finally, multivariate linear regression models were constructed to analyze the factors associated with MetS scores in the males and females separately. All p values were 2-tailed, and the significance level was < 0.05. Statistical analyses were performed using SPSS 27 (SPSS, Inc., Chicago, IL). Results Demographic and general clinical data of enrolled patients The demographic data and general clinical data of the included patients, as well as the gender differences between these data, are shown in Table 1. Compared to male, the WC was significantly higher (t =− 2.05, p = 0.041), and the CGI-SI was lower (t = 2.21, p = 0.035) in female patients.Table 1 Gender differences in demographic and general clinical data Index Total patients (n = 668) Male (n = 244) Female (n = 424) t/χ2 p-value Age—years 29.58 ± 7.18 29.23 ± 6.87 29.77 ± 7.35 − 0.94 0.348 Course of disease—years 5.14 ± 4.11 5.26 ± 4.6 5.07 ± 4.78 0.49 0.623 Onset age—years 24.44 ± 6.40 23.98 ± 6.32 24.7 ± 6.43 − 1.42 0.157 Marital status—(n, %) 0.64 0.424  Spousal 312, 46.71% 109, 44.67% 203, 47.88%  Others 356, 53.29% 135, 55.33% 221, 52.12% Educational background—(n, %) 3.56 0.059  Junior school and below 440, 65.87% 158, 64.75% 282, 66.51%  High school and above 228, 34.13% 86, 35.25% 142, 33.49% MetS dimensions  WC—cm 78.32 ± 9.05 77.38 ± 9.06 78.87 ± 9.01 − 2.05 0.041*  FBG—mmol/L 5.57 ± 0.49 5.55 ± 0.5 5.59 ± 0.48 − 1.00 0.319  SBP—mmHg 113.08 ± 12.36 112.64 ± 11.53 113.34 ± 12.82 − 0.71 0.477  DBP—mmHg 75.16 ± 8.71 75.08 ± 7.95 75.2 ± 9.12 − 0.18 0.861  TG—mmol/L 1.09 ± 0.55 1.08 ± 0.55 1.1 ± 0.56 − 0.36 0.720  HDL-C—mmol/L 1.18 ± 0.23 1.18 ± 0.25 1.19 ± 0.22 − 0.40 0.689  TC—mmol/L 3.85 ± 0.72 3.84 ± 0.7 3.85 ± 0.72 − 0.16 0.875  LDL-C—mmol/L 2.18 ± 0.58 2.19 ± 0.58 2.18 ± 0.59 0.28 0.778  RBC—1012/L 4.55 ± 0.47 4.52 ± 0.51 4.56 ± 0.45 − 1.05 0.293  HGB—g/L 135.92 ± 17.32 135.44 ± 18.28 136.2 ± 16.76 − 0.55 0.584  WBC—109/L 6.91 ± 2.00 7.07 ± 2.15 6.82 ± 1.91 1.52 0.130  PLT—109/L 242.33 ± 57.46 244.59 ± 60.17 241.03 ± 55.87 0.77 0.440  BUN—mmol/L 4.49 ± 1.77 4.59 ± 1.76 4.43 ± 1.77 1.18 0.239  CRE—mmol/L 57.92 ± 12.56 58.07 ± 12.41 57.83 ± 12.66 0.24 0.814  UA—mmol/L 353.19 ± 123.88 418.34 ± 128.97 410.23 ± 120.91 0.81 0.416  TSH—uIU/mL 1.70 ± 0.72 1.72 ± 0.71 1.68 ± 0.72 0.70 0.481  FT3—pmol/L 4.85 ± 0.69 4.88 ± 0.68 4.83 ± 0.69 0.79 0.433  FT4—pmol/L 16.94 ± 3.15 17.03 ± 3.21 16.9 ± 3.13 0.51 0.609  CGI-SI 5.36 ± 0.62 5.43 ± 0.62 5.32 ± 0.62 2.12 0.035*  PANSS 88.90 ± 11.43 89.43 ± 11.52 88.6 ± 11.38 0.90 0.367   Positive factor 15.90 ± 3.51 15.82 ± 3.57 15.94 ± 3.48 − 0.42 0.678   Negative factor 28.23 ± 6.22 28.64 ± 6.39 27.99 ± 6.12 1.29 0.199   Excitement factor 12.71 ± 4.44 12.85 ± 4.4 12.63 ± 4.46 0.60 0.549   Anxiety/depression factor 15.43 ± 4.50 15.21 ± 4.71 15.55 ± 4.38 − 0.92 0.356   Cognitive factor 16.48 ± 4.41 16.68 ± 4.67 16.36 ± 4.25 0.91 0.361 WC waist circumference, FBG fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, HDL-C high-density lipoprotein cholesterol, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, RBC red blood cell, HGB hemoglobin, WBC white blood cell, PLT platelet, BUN blood urea nitrogen, CRE blood creatinine, UA blood uric acid, TSH thyroid stimulating hormone, FT3 free triiodothyronine, FT4 free tetraiodothyronine, PANSS Positive and Negative Syndrome Scale, CGI-SI Clinical Global Impression Scale—Severity of Illness. *p < 0.05 Gender differences in the prevalence, demographic and clinical features of MetS in Sch patients The overall prevalence of MetS in our included sample was 10.93% (73/668), with 6.56% (16/244) of male patients and 13.44% (57/424) of female patients. The prevalence was significantly higher in females than in males (χ2= 7.54, p = 0.006). The MetS-z score for males with MetS was (− 0.27 ± 0.89) and for females was (0.09 ± 0.78), with no gender differences in MetS-z scores (t = − 1.54, p = 0.128). As shown in Table 2, ANOVA was performed to examine the interaction between MetS and gender. There was extensive difference in various clinical parameters between different clinical subgroups, for example WC (F = 95.45, p < 0.001), FBG (F = 8.24, p = 0.004), SBP (F = 53.71, p < 0.001), DBP (F = 80.06, p < 0.001), TG (F = 74.79, p < 0.001), TC (F = 33.95, p < 0.001), LDL-C (F = 23.22, p < 0.001), RBC (F = 6.89, p = 0.009), HGB (F = 8.35, p = 0.004), WBC (F = 9.02, p = 0.003), PLT (F = 5.20, p = 0.023), FT4 (F = 19.35, p < 0.001), CGI-SI (F = 10.63, p = 0.001). Meanwhile, gender × subgroup had an effect on age (F = 7.24, p < 0.001), onset age (F = 5.59, p = 0.018) and SBP (F = 5.23, p = 0.023).Table 2 Demographic and clinical characteristics between enrolled patients with and without MetS, grouped by gender Parameters MetS (n = 73) Non-MetS (n = 595) Gender F (p -value) Diagnosis F (p -value) Gender × diagnosis F (p -value) Male (n = 16) Female (n = 57) Male (n = 228) Female (n = 367) Age—years 31.08 ± 7.72 26.59 ± 5.55 29.10 ± 6.80 30.27 ± 7.47 2.50(0.114) 0.66 (0.419) 7.24 (< .001*) Course of disease—years 6.70 ± 5.30 5.33 ± 3.88 5.15 ± 4.55 5.03 ± 4.91 1.16 (0.283) 1.76 (0.185) 0.80(0.371) Onset age—years 24.37 ± 5.77 21.26 ± 4.69 23.95 ± 6.36 25.24 ± 6.51 0.96 (0.328) 3.63 (0.057) 5.59 (0.018*) MetS dimensions  WC—cm 86.53 ± 10.3 90.64 ± 6.52 76.74 ± 8.63 77.04 ± 7.89 3.39 (0.066) 95.45 (< .001*) 2.53 (0.112)  FBG—mmol/L 5.87 ± 0.50 5.65 ± 0.57 5.53 ± 0.49 5.58 ± 0.46 1.42 (0.234) 8.24 (0.004*) 3.70 (0.055)  SBP—mmHg 120.63 ± 14.82 127.46 ± 14.91 112.07 ± 11.09 111.15 ± 10.96 3.03 (0.082) 53.71(< .001*) 5.23 (0.023*)  DBP—mmHg 84.38 ± 10.94 84.95 ± 10.89 74.43 ± 7.29 73.69 ± 7.81 0.01 (0.944) 80.06 (< .001*) 0.31 (0.580)  TG—mmol/L 1.77 ± 0.55 1.73 ± 0.60 1.04 ± 0.51 1.00 ± 0.49 0.21 (0.646) 94.79 (< .001*) 0.00 (0.997)  HDL-C—mmol/L 1.22 ± 0.19 1.15 ± 0.14 1.17 ± 0.26 1.19 ± 0.23 0.53 (0.467) 0.00 (0.950) 1.41 (0.236)  TC—mmol/L 4.38 ± 0.70 4.39 ± 0.67 3.80 ± 0.69 3.77 ± 0.7 0.02 (0.8901) 33.95 (< .001*) 0.05 (0.828)  LDL-C—mmol/L 2.57 ± 0.81 2.53 ± 0.65 2.16 ± 0.55 2.12 ± 0.56 0.19 (0.661) 23.22 (< .001*) 0.00 (0.950)  RBC—1012/L 4.62 ± 0.30 4.78 ± 0.32 4.51 ± 0.52 4.53 ± 0.46 1.53 (0.216) 6.89 (0.009*) 1.05 (0.306)  HGB—g/L 139.62 ± 12.57 144.96 ± 12.08 135.14 ± 18.6 134.84 ± 16.98 0.99 (0.320) 8.35 (0.004*) 1.25 (0.264)  WBC—109/L 7.59 ± 2.28 7.86 ± 1.95 7.03 ± 2.14 6.66 ± 1.85 0.03 (0.866) 9.02 (0.003*) 1.19 (0.275)  PLT—109/L 263.81 ± 82.21 256.58 ± 52.17 243.25 ± 58.32 238.61 ± 56.1 0.49 (0.483) 5.20 (0.023*) 0.24 (0.878)  BUN—mmol/L 4.28 ± 1.22 4.08 ± 1.13 4.61 ± 1.79 4.48 ± 1.85 0.41 (0.524) 2.02 (0.156) 0.01 (0.908)  CRE—mmol/L 55.56 ± 17.42 61.78 ± 18.09 58.25 ± 12.01 57.22 ± 11.51 1.99 (0.160) 0.26 (0.613) 3.85 (0.050)  UA—mmol/L 425.4 ± 129.32 401.12 ± 83.15 417.84 ± 129.21 411.65 ± 125.79 0.64 (0.405) 0.01 (0.936) 0.25 (0.621)  TSH—uIU/mL 1.83 ± 0.73 1.74 ± 0.70 1.71 ± 0.71 1.67 ± 0.72 0.37 (0.543) 0.75 (0.388) 0.04 (0.835)  FT3—pmol/L 4.84 ± 0.75 4.68 ± 0.77 4.88 ± 0.67 4.86 ± 0.68 0.80 (0.372) 1.21 (0.271) 0.46 (0.498)  FT4—pmol/L 14.73 ± 2.32 15.53 ± 3.30 17.19 ± 3.20 17.11 ± 3.05 0.63 (0.429) 19.35 (< .001*) 0.93 (0.335)  CGI-SI 5.13 ± 0.72 5.09 ± 0.43 5.45 ± 0.61 5.36 ± 0.64 0.50 (0.482) 10.63 (0.001*) 0.09 (0.770)  PANSS 90.69 ± 14.54 84.74 ± 11.6 89.34 ± 11.32 89.2 ± 11.24 3.29 (0.070) 0.86 (0.354) 2.99 (0.084)   Positive factor 16.31 ± 3.24 15.18 ± 3.17 15.79 ± 3.60 16.06 ± 3.51 0.70 (0.403) 0.12 (0.727) 1.85 (0.174)   Negative factor 29.06 ± 7.19 27.09 ± 7.14 28.61 ± 6.34 28.13 ± 5.94 1.78 (0.183) 0.10 (0.749) 0.67 (0.413)   Excitement factor 12.44 ± 5.35 11.33 ± 4.64 12.88 ± 4.33 12.84 ± 4.41 0.77 (0.381) 2.21 (0.138) 0.66 (0.416)   Anxiety/depression factor 14.31 ± 4.29 14.30 ± 3.97 15.28 ± 4.74 15.74 ± 4.41 0.12 (0.734) 3.30 (0.070) 0.13 (0.718)   Cognitive factor 17.94 ± 5.78 16.53 ± 3.86 16.6 ± 4.58 16.34 ± 4.31 1.65 (0.199) 1.39 (0.240) 0.78 (0.377) WC waist circumference, FBG fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, HDL-C high-density lipoprotein cholesterol, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, RBC red blood cell, HGB hemoglobin, WBC white blood cell, PLT platelet, BUN blood urea nitrogen, CRE blood creatinine, UA blood uric acid, TSH thyroid stimulating hormone, FT3 free triiodothyronine, FT4 free tetraiodothyronine, PANSS Positive and Negative Syndrome Scale, CGI-SI Clinical Global Impression Scale—Severity of Illness. *p < 0.05 The related factors of MetS in male Sch patients In the male patients, TC (r = 0.20, p = 0.001), LDL-C (r = 0.17, p = 0.017) were positively correlated with MetS, but FT4 (r = − 0.19, p = 0.003), CGI-SI (r = − 0.13, p = 0.044) were negatively correlated with MetS (Table 3). Further, we used MetS (marked as 0 = non-MetS, 1 = MetS) as the dependent variable, take all clinical parameters above significantly related to MetS as independent variables, and constructed a binary logistic regression model to analyze the influencing factors of MetS. It was found that TC (OR = 9.41, 95%CI 1.381–48.87, p = 0.008) was risk factors for MetS, while, FT4 (OR = 0.72, 95%CI 0.57–0.90, p = 0.004) and CGI-SI (OR = 0.32, 95%CI 0.12–0.85, p = 0.023) were predictive factor (Table 4). Finally, multiple linear regression models (Input) constructed with MetS scores as the dependent variable and clinical variables associated with MetS as the independent variables, no variables associated with MetS scores were found (Table 5).Table 3 Correlation between MetS and demographic and clinical variable in male and female patients Characteristic Male (n = 244) Female (n = 424) r(p) r(p) Age—years 0.07(0.267) − 0.17(< .001*) Course of disease—years 0.08(0.195) 0.02(0.659) Onset age—years 0.02(0.794) − 0.21(< .001*) Marital status (spousal vs. others) 0.03(0.659) − 0.13(0.008*) High school and above (yes vs. no) 0.01(0.846) − 0.05(0.353) TC—mmol/L 0.20(0.001*) 0.29(< .001*) LDL-C—mmol/L 0.17(0.007*) 0.24(< .001*) RBC—1012/L 0.05(0.403) 0.19(< .001*) HGB—g/L 0.06(0.344) 0.21(< .001*) WBC—109/L 0.06(0.317) 0.21(< .001*) PLT—109/L 0.09(0.187) 0.11(0.024*) BUN—mmol/L − 0.05(0.455) − 0.08(0.113) CRE—mmol/L − 0.05(0.403) 0.12(0.011*) UA—mmol/L 0.02(0.820) − 0.03(0.542) TSH—uIU/mL 0.04(0.538) 0.03(0.498) FT3—pmol/L − 0.02(0.807) − 0.09(0.068) FT4—pmol/L − 0.19(0.003*) − 0.17(< .001*) CGI-SI − 0.13(0.044*) − 0.15(0.002*) PANSS 0.03(0.653) − 0.13(0.006*)  Positive factor 0.04(0.572) − 0.09(0.074)  Negative factor 0.02(0.783) − 0.06(0.230)  Excitement factor − 0.03(0.700) − 0.12(0.018*)  Anxiety/depression factor − 0.05(0.429) − 0.11(0.020*)  Cognitive factor 0.07(0.267) 0.02(0.753) TC total cholesterol, LDL-C low-density lipoprotein cholesterol, RBC red blood cell, HGB hemoglobin, WBC white blood cell, PLT platelet, BUN blood urea nitrogen, CRE blood creatinine, UA blood uric acid, TSH thyroid stimulating hormone, FT3 free triiodothyronine, FT4 free tetraiodothyronine, PANSS Positive and Negative Syndrome Scale, CGI-SI Clinical Global Impression Scale—Severity of Illness. *p < 0.05 Table 4 Binary logistic regression analyses of determinants of MetS in male and female patients Coefficients Std. error Wald p value 95% CI for EXP (B) B Exp(B) Lower Upper Male TC—mmol/L 2.24 0.84 7.12 0.008* 9.41 1.81 48.87 LDL-C—mmHg − 1.10 0.85 1.65 0.199 0.33 0.06 1.78 FT4—pmol/L − 0.34 0.12 8.12 0.004* 0.72 0.57 0.90 CGI-SI − 1.13 0.50 5.20 0.023* 0.32 0.12 0.85 Female Age—years − 0.16 0.04 20.63  < .001* 0.85 0.79 0.91 TC—mmol/L 1.70 0.29 34.55  < .001* 5.47 3.10 9.64 RBC—1012/L 1.89 0.46 16.60  < .001* 6.59 2.66 16.33 WBC—109/L 0.34 0.10 12.38  < .001* 1.40 1.16 1.69 FT4—pmol/L − 0.16 0.06 7.06 0.008* 0.85 0.76 0.96 CGI-SI − 1.57 0.35 20.45  < .001* 0.21 0.11 0.41 TC total cholesterol, LDL-C low-density lipoprotein cholesterol, FT4 free tetraiodothyronine, CGI-SI Clinical Global Impression Scale—Severity of Illness, TC total cholesterol, RBC red blood cell, WBC white blood cell. *p < 0.05 Table 5 Correlates affecting MetS scores in male and female patients: a multiple linear regression model Coefficients Std. error t p-value 95% CI B Lower Upper Male  TC—mmol/L 0.13 0.73 0.18 0.858 − 1.48 1.74  LDL-C—mmol/L − 0.07 0.64 − 0.11 0.915 − 1.47 1.33  FT4—pmol/L − 0.11 0.13 − 0.87 0.401 − 0.39 0.17  CGI—SI − 0.01 0.41 − 0.02 0.988 − 0.90 0.89 Female  Age—years 0.10 0.03 3.31 0.002* 0.04 0.15  Onset age—years − 0.07 0.03 − 2.10 0.041* − 0.14 0.00  LDL-C—mmol/L 0.37 0.16 2.32 0.024* 0.05 0.69  HGB—g/L − 0.05 0.01 − 3.41 0.001* − 0.07 -0.02  WBC—109/L 0.12 0.06 1.91 0.062 − 0.01 0.24  CRE—mmol/L 0.03 0.01 3.76  < .001* 0.01 0.04  PANSS 0.03 0.01 3.64 0.001* 0.02 0.05 TC total cholesterol, LDL-C low-density lipoprotein cholesterol, FT4 free tetraiodothyronine, CGI-SI Clinical Global Impression Scale—Severity of Illness, HGB hemoglobin, WBC white blood cell, CRE blood creatinine, PANSS Positive and Negative Syndrome Scale. *p < 0.05 The related factors of MetS in female Sch patients In the female patients, TC (r = 0.29, p < 0.001), LDL-C (r = 0.24, p < 0.001), RBC (r = 0.19, p < 0.001), HGB (r = 0.21, p < 0.001), WBC (r = 0.21, p < 0.001), PLT (r = 0.11, p = 0.024), CRE (r = 0.12, p = 0.011) were positively correlated with MetS, but age (r = − 0.17, p < 0.001), onset age (r = − 0.21, p < 0.001), FT4 (r = 0.43, p < 0.001), Marital status (spousal vs. others) (r = -0.13, p = 0.008), CGI-SI (r = − 0.15, p = 0.002), PANSS (r = − 0.13, p = 0.006), excitement factor (r = − 0.12, p = 0.018), anxiety/depression factor (r = − 0.11, p = 0.018) were negatively correlated with MetS (Table 3). Further, we used MetS as the dependent variable, take the above clinical parameters related to MetS as independent variables, and constructed a binary logistic regression model to analyze the influencing factors of MetS. It was found that TC (OR = 5.47, 95%CI 3.10–9.64, p < 0.001), RBC (OR = 6.59, 95%CI 2.66–16.33, p < 0.001), WBC (OR = 1.40, 95%CI 1.16–1.69, p < 0.001) were independent predictors of MetS, while, age (OR = 0.85, 95%CI 0.79–0.91, p < 0.001), FT4 (OR = 0.85, 95%CI 0.76–0.96, p = 0.008) and CGI-SI (OR = 0.21, 95%CI 0.11–0.41, p < 0.001) were predictive factors (Table 4). Finally, multiple linear regression models constructed with MetS scores as the dependent variable and clinical variables associated with MetS as the independent variables, We found that age (B = 0.10, t = 3.31, p = 0.002), LDL-C (B = 0.37, t = 2.32, p = 0.024), CRE (B = 0.03, t = 3.76, p < 0.001) and PANSS (B = 0.03, t = 3.64, p = 0.001) were risk factors for higher MetS scores, while onset age (B = − 0.07, t = − 2.10, p = 0.041) and HGB (B = − 0.05, t = − 3.41, p = 0.001) were protective factors for the higher MetS score (Table 5). Discussion The present study analyzed and reported gender differences in the prevalence of MetS and the factors influencing it in patients with FTDN Sch. The main findings of our study were as follows: 1. the prevalence of MetS was significantly higher in females than in males. 2. There were gender differences in the risk factors for MetS. 3. The factors associated with the severity of MetS also differed by gender. Several studies and meta-analyses have shown that the presence of metabolic disorders at the onset of primary schizophrenia [42–44] may be closely related to psychopathology [45] and the existence of common genetic pathways and variants in this psychiatric disorder and MetS [46, 47]. In the present study, we report a significant gender difference in the prevalence of MetS in the included sample (female vs. male: 13.44% vs. 6.56%). The small sample from Iran reported gender differences in the prevalence of MetS in patients with first-episode Sch using three different MetS diagnostic criteria (all were more higher in females) [48]. Another study with 303 Spanish FTDN Sch patients reported a significantly higher prevalence of high WC (a component of MetS) in females than in males [36]. In conclusion, the presence of sex differences in the prevalence of MetS may be an important clinical feature of FTDN Sch patients; whereas estrogen may be an important contributor in causing this difference [49, 50]. However, Yongjie Zhou et al. reported a higher but gender-neutral prevalence of MetS in FTDN Sch patients (female vs. male: 21.1% vs. 20.1%) [51]. This may be related to the greater severity of psychopathological symptoms [51, 52] and more stringent diagnostic criteria for MetS in the patients included in this study. Another of our key findings is that there are gender differences in the factors influencing MetS in the target population. In terms of risk factors for MetS, in addition to TC as a common risk factor for both subgroups, females are affected by a broader range of clinical parameters, such as RBC and WBC. Similarly, for protective factors for MetS, FT4 and CGI-SI are common to both male and female patients, but higher age is only a protective factor for the females. Although a wider range of clinical parameters were not included as in our study, a previous study similarly reported gender differences in the contributing factors to MetS in drug naïve schizophrenia patients, and again the female subgroup had a wider range of risk factors (the contributing factors differed from those reported in ours) [51]. Some studies have reported that thyroid function [53] and negative symptoms [54] may be one of the reasons for gender differences in MetS metabolism-related parameters in patients with schizophrenia. However, unfortunately, in the present study, there were no gender differences in the three components of thyroid function (TSH, FT3, FT4) and negative symptoms in the included samples. In conclusion, the reasons for the more diverse and widespread MetS-related factors in the female subgroup of the FTDN Sch population remain to be further explored and confirmed. The severity of MetS is a topic that is rarely addressed, especially in Sch patients, a population vulnerable to MetS. After our exploration, we found gender differences in the factors affecting MetS scores, specifically, the female subgroup presented age, LDL-C, CRE and PANSS as risk factors, while onset age, and HGB were protective factors. However, in the male subgroup, no relevant factors were found. In a large sample PREDIMED-Plus study, the investigators reported that MetS severity was associated with risk of depression [55]. Unfortunately, there were no gender differences in depression factor scores in our included sample. The National Health and Nutrition Examination Survey of the general adult population from Korea found that progression scores for MetS severity were significantly higher in women than in men [56], which would seem to provide some side support for our findings that MetS severity affects more women patients than men. Furthermore, we cannot completely deny that since the age range of our included patients was 18–49 years, sex hormones may still be an important contributor to this gender difference [57]. However, due to the inadequacy of studies involving the severity of MetS, our findings still need further validation. Our study also has some shortcomings. Firstly, as a cross-sectional study, we were unable to determine causality and a prospective study will be set up in the future to fill this gap. Secondly, there was a gender imbalance in our included sample, meaning that the sample size of males was significantly lower than females, which may contribute to the statistical efficacy of the regression analysis for male patients. In summary, there are significant gender differences in the prevalence of MetS and its factors among patients with FTDN Sch. The prevalence of MetS is higher and the factors that influence MetS are more numerous and extensive in females. Further prospective studies are needed in the future to determine the mechanisms and reasons for this discrepancy. In clinical practice, interventions for MetS in females need to be more targeted and specific clinical strategies than for males. Abbreviations Aps Antipsychotics BDNF Brain-derived neurotrophic factor BUN Blood urea nitrogen CGI-SI Clinical Global Impression Scale—Severity of Illness CRE Blood creatinine CVD Cardiovascular disease DBP Diastolic blood pressure FBG Fasting blood glucose FTDN First-treatment and drug-naïve FT3 Free triiodothyronine FT4 Free tetraiodothyronine HDL-C High-density lipoprotein cholesterol HGB Hemoglobin ICD-10 International Classification of Diseases 10th Revision LDL-C Low-density lipoprotein cholesterol MAP Mean average pressure MetS Metabolic syndrome PANSS Positive and Negative Symptom Scales PLT Platelet RBC Red blood cell SBP Systolic blood pressure Sch Schizophrenia TC Total cholesterol TG Triglycerides TSH Thyroid stimulating hormone UA Blood uric acid WBC White blood cell WC Waist circumference Acknowledgements We are grateful to all the medical staffs and patients in our study and to those who contributed to the diagnosis and clinical evaluation of the subjects. Author contributions JM and YZ made substantial contributions to conception and design of the study. KZ drafted the manuscript. SW had polished and re-edited the language and logic of the article. LZ was responsible for setting up and complement and modify the contents of the manuscript. JM gave final approval of the version to be published. Funding The authors declare that there is no funding. Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The ethics committees of the Wuhan mental health center reviewed and approved this study. All subject guardians knew about this study and signed informed consent. All procedures carried out in studies conformed to the 1964 Helsinki Declaration and its subsequent amendments or similar ethical standards. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Kuan Zeng and Shuo Wang contributed equally to this work. ==== Refs References 1. Fahed G Aoun L Bou Zerdan M Allam S Bou Zerdan M Bouferraa Y Assi HI Metabolic syndrome: updates on pathophysiology and management in 2021 Int J Mol Sci 2022 10.3390/ijms23020786 35054972 2. Saklayen MG The global epidemic of the metabolic syndrome Curr Hypertens Rep 2018 20 2 12 10.1007/s11906-018-0812-z 29480368 3. Bentley-Lewis R Koruda K Seely EW The metabolic syndrome in women Nat Clin Pract Endocrinol Metab 2007 3 10 696 704 10.1038/ncpendmet0616 17893688 4. Afshin A Forouzanfar MH Reitsma MB Sur P Estep K Lee A Marczak L Mokdad AH Moradi-Lakeh M Naghavi M Health effects of overweight and obesity in 195 Countries over 25 years N Engl J Med 2017 377 1 13 27 10.1056/NEJMoa1614362 28604169 5. Ranasinghe P Mathangasinghe Y Jayawardena R Hills AP Misra A Prevalence and trends of metabolic syndrome among adults in the Asia-Pacific region: a systematic review BMC Public Health 2017 17 1 101 10.1186/s12889-017-4041-1 28109251 6. Xi B He D Hu Y Zhou D Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the China Health and Nutrition Survey in 2009 Prev Med 2013 57 6 867 871 10.1016/j.ypmed.2013.09.023 24103567 7. Yao F Bo Y Zhao L Li Y Ju L Fang H Piao W Yu D Lao X Prevalence and influencing factors of metabolic syndrome among Adults in China from 2015 to 2017 Nutrients 2021 10.3390/nu13124475 34960027 8. Liu B Chen G Zhao R Huang D Tao L Temporal trends in the prevalence of metabolic syndrome among middle-aged and elderly adults from 2011 to 2015 in China: the China health and retirement longitudinal study (CHARLS) BMC Public Health 2021 21 1 1045 10.1186/s12889-021-11042-x 34078325 9. Krishnamoorthy Y Rajaa S Murali S Rehman T Sahoo J Kar SS Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis PLoS ONE 2020 15 10 e0240971 10.1371/journal.pone.0240971 33075086 10. Aoki R Saito T Ninomiya K Shimasaki A Ashizawa T Ito K Ikeda M Iwata N Shared genetic components between metabolic syndrome and schizophrenia: genetic correlation using multipopulation data sets Psychiatry Clin Neurosci 2022 76 8 361 366 10.1111/pcn.13372 35536160 11. McCutcheon RA Reis Marques T Howes OD Schizophrenia-an overview JAMA Psychiat 2020 77 2 201 210 10.1001/jamapsychiatry.2019.3360 12. Saha S Chant D Welham J McGrath J A systematic review of the prevalence of schizophrenia PLoS Med 2005 2 5 e141 10.1371/journal.pmed.0020141 15916472 13. Chesney E Goodwin GM Fazel S Risks of all-cause and suicide mortality in mental disorders: a meta-review World Psychiatry 2014 13 2 153 160 10.1002/wps.20128 24890068 14. Laursen TM Nordentoft M Mortensen PB Excess early mortality in schizophrenia Annu Rev Clin Psychol 2014 10 425 448 10.1146/annurev-clinpsy-032813-153657 24313570 15. Laursen TM Causes of premature mortality in schizophrenia: a review of literature published in 2018 Curr Opin Psychiatry 2019 32 5 388 393 10.1097/YCO.0000000000000530 31135491 16. Piotrowski P Gondek TM Królicka-Deręgowska A Misiak B Adamowski T Kiejna A Causes of mortality in schizophrenia: an updated review of European studies Psychiatr Danub 2017 29 2 108 120 10.24869/psyd.2017.108 28636568 17. Chang SC Goh KK Lu ML Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives World J Psychiatry 2021 11 10 696 710 10.5498/wjp.v11.i10.696 34733637 18. Mazereel V Detraux J Vancampfort D van Winkel R De Hert M Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness Front Endocrinol 2020 11 573479 10.3389/fendo.2020.573479 19. Molina JD Avila S Rubio G López-Muñoz F Metabolomic connections between Schizophrenia, antipsychotic drugs and metabolic syndrome: a variety of players Curr Pharm Des 2021 27 39 4049 4061 10.2174/1381612827666210804110139 34348619 20. Mitchell AJ Vancampfort D Sweers K van Winkel R Yu W De Hert M Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis Schizophr Bull 2013 39 2 306 318 10.1093/schbul/sbr148 22207632 21. Thakore JH Metabolic disturbance in first-episode schizophrenia Br J Psychiatry Suppl 2004 47 S76 79 10.1192/bjp.184.47.s76 15056598 22. Dasgupta A Singh OP Rout JK Saha T Mandal S Insulin resistance and metabolic profile in antipsychotic naïve schizophrenia patients Prog Neuropsychopharmacol Biol Psychiatry 2010 34 7 1202 1207 10.1016/j.pnpbp.2010.06.011 20600470 23. Wu X Huang Z Wu R Zhong Z Wei Q Wang H Diao F Wang J Zheng L Zhao J The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls Schizophr Res 2013 150 1 157 162 10.1016/j.schres.2013.07.051 23998954 24. Liang J Cai Y Xue X Li X Li Z Xu C Xie G Yu Y Does schizophrenia itself cause obesity? Front Psychiatry 2022 13 934384 10.3389/fpsyt.2022.934384 35815040 25. Chen DC Du XD Yin GZ Yang KB Nie Y Wang N Li YL Xiu MH He SC Yang FD Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits Psychol Med 2016 46 15 3219 3230 10.1017/S0033291716001902 27604840 26. Brzezinski-Sinai NA Seeman MV Women and schizophrenia: planning for the future Future Neurol 2017 12 2 89 99 10.2217/fnl-2016-0031 27. Cotton SM Lambert M Schimmelmann BG Foley DL Morley KI McGorry PD Conus P Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis Schizophr Res 2009 114 1–3 17 24 10.1016/j.schres.2009.07.002 19635660 28. Haro JM Ciudad A Alonso J Bousoño M Suárez D Novick D Gilaberte I Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years Actas Esp Psiquiatr 2008 36 4 187 196 18461495 29. Morgan VA Castle DJ Jablensky AV Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders Aust N Z J Psychiatry 2008 42 1 74 82 10.1080/00048670701732699 18058447 30. Chen S Broqueres-You D Yang G Wang Z Li Y Yang F Tan Y Male sex may be associated with higher metabolic risk in first-episode schizophrenia patients: a preliminary study Asian J Psychiatr 2016 21 25 30 10.1016/j.ajp.2015.12.001 27208452 31. Chen DC Zhou MA Zhou DH Xiu MH Wu GY Kosten TR Zhang XY Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics Psychiatry Res 2011 186 2–3 451 453 10.1016/j.psychres.2010.07.054 20797801 32. Yang F Wang K Du X Deng H Wu HE Yin G Ning Y Huang X Teixeira AL de Quevedo J Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia Psychopharmacology 2019 236 2 753 762 10.1007/s00213-018-5107-1 30456540 33. Yang W Zheng L Zheng B Zeng S Li J Liang B Zhu J Zhang M A meta-analysis of abnormal glucose metabolism in first-episode drug-naive schizophrenia Psychiatr Danub 2020 32 1 46 54 10.24869/psyd.2020.46 32303029 34. Lang X Zhou Y Zhao L Gu Y Wu X Zhao Y Li Z Zhang X Differences in patterns of metabolic abnormality and metabolic syndrome between early-onset and adult-onset first-episode drug-naive schizophrenia patients Psychoneuroendocrinology 2021 132 105344 10.1016/j.psyneuen.2021.105344 34274733 35. Anjum S Bathla M Panchal S Singh GP Singh M Metabolic syndrome in drug naïve schizophrenic patients Diabetes Metab Syndr 2018 12 2 135 140 10.1016/j.dsx.2017.11.006 29191416 36. Garrido-Torres N Ruiz-Veguilla M Alameda L Canal-Rivero M Ruiz MJ Gómez-Revuelta M Ayesa-Arriola R Rubio-García A Crespo-Facorro B Vázquez-Bourgon J Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: baseline results from the PAFIP cohort Schizophr Res 2022 246 277 285 10.1016/j.schres.2022.07.007 35878542 37. Saloojee S Burns JK Motala AA Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care Early Interv Psychiatry 2018 12 6 1137 1143 10.1111/eip.12428 28402033 38. Society CD: Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition). Chinese Journal of Practical Internal Medicine 2018, 38(04):292–344. 39. Kim JH Kim SY Lee J Oh KJ Kim YB Cho ZH Evaluation of the factor structure of symptoms in patients with schizophrenia Psychiatry Res 2012 197 3 285 289 10.1016/j.psychres.2011.10.006 22364933 40. Wu M Shu Y Wang L Song L Chen S Liu Y Bi J Li D Yang Y Hu Y Metabolic syndrome severity score and the progression of CKD Eur J Clin Invest 2022 52 1 e13646 10.1111/eci.13646 34197633 41. Wijndaele K Beunen G Duvigneaud N Matton L Duquet W Thomis M Lefevre J Philippaerts RM A continuous metabolic syndrome risk score: utility for epidemiological analyses Diabetes Care 2006 29 10 2329 10.2337/dc06-1341 17003322 42. Shah P Iwata Y Caravaggio F Plitman E Brown EE Kim J Chan N Hahn M Remington G Gerretsen P Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: a systematic review and meta-analysis Schizophr Res 2019 208 420 429 10.1016/j.schres.2019.01.005 30685395 43. Çakici N Sutterland AL Penninx B Dalm VA de Haan L van Beveren NJM Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis Brain Behav Immun 2020 88 547 558 10.1016/j.bbi.2020.04.039 32330592 44. Pillinger T Beck K Gobjila C Donocik JG Jauhar S Howes OD Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis JAMA Psychiat 2017 74 3 261 269 10.1001/jamapsychiatry.2016.3803 45. Çakici N Bot M Lamers F Janssen T van der Spek PJ de Haan L Bahn S Penninx B van Beveren NJM Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis Eur Neuropsychopharmacol 2019 29 7 835 846 10.1016/j.euroneuro.2019.05.010 31230885 46. Postolache TT Del Bosque-Plata L Jabbour S Vergare M Wu R Gragnoli C Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome Am J Med Genet B Neuropsychiatr Genet 2019 180 3 186 203 10.1002/ajmg.b.32712 30729689 47. Lane JM Liang J Vlasac I Anderson SG Bechtold DA Bowden J Emsley R Gill S Little MA Luik AI Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits Nat Genet 2017 49 2 274 281 10.1038/ng.3749 27992416 48. Sahpolat M Ari M Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey Nord J Psychiatry 2021 75 1 73 78 10.1080/08039488.2020.1815080 32886012 49. Palmer BF Clegg DJ The sexual dimorphism of obesity Mol Cell Endocrinol 2015 402 113 119 10.1016/j.mce.2014.11.029 25578600 50. da Silva TL Ravindran AV Contribution of sex hormones to gender differences in schizophrenia: a review Asian J Psychiatr 2015 18 2 14 10.1016/j.ajp.2015.07.016 26321672 51. Zhou Y Song X Guo Y Lang X Li Z Zhang XY Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia Psychoneuroendocrinology 2021 124 105061 10.1016/j.psyneuen.2020.105061 33291004 52. Lang X Liu Q Fang H Zhou Y Forster MT Li Z Zhang X The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia Psychopharmacology 2021 238 12 3643 3652 10.1007/s00213-021-05983-9 34586464 53. Kalinowska S Trześniowska-Drukała B Safranow K Pełka-Wysiecka J Kłoda K Misiak B Samochowiec J Association between thyroid function and metabolic syndrome in male and female schizophrenia patients Psychiatry Res 2019 274 167 175 10.1016/j.psychres.2019.02.029 30802688 54. Wójciak P Domowicz K Rybakowski JK Metabolic indices in schizophrenia: association of negative symptoms with higher HDL cholesterol in female patients World J Biol Psychiatry 2021 22 7 552 556 10.1080/15622975.2020.1849796 33176545 55. Gallardo-Alfaro L Bibiloni MDM Mascaró CM Montemayor S Ruiz-Canela M Salas-Salvadó J Corella D Fitó M Romaguera D Vioque J Leisure-time physical activity, sedentary behaviour and diet quality are associated with metabolic syndrome severity: the PREDIMED-plus study Nutrients 2020 10.3390/nu12041013 32272653 56. Huh JH Lee JH Moon JS Sung KC Kim JY Kang DR Metabolic syndrome severity score in Korean adults: analysis of the 2010–2015 Korea national health and nutrition examination survey J Korean Med Sci 2019 34 6 e48 10.3346/jkms.2019.34.e48 30787681 57. Iyer A Kauter K Brown L Gender differences in metabolic syndrome: a key research issue? Endocr Metab Immune Disord Drug Targets 2011 11 3 182 188 10.2174/187153011796429808 21831031